Mitsui & Co. Ltd. ADS (MITSY) Financials Nov 14, 2014, 8:10
Mitsui & Co. Ltd. ADS (MITSY) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Mitsui & Co. Ltd. ADS
Fiscal year is April-March. All values JPY millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 4.07T 4.67T 5.23T 4.91T 5.73T
Cost of Goods Sold (COGS) incl. D&A 3.39T 3.83T 4.38T 4.13T 4.88T
COGS excluding D&A 3.25T 3.68T 4.22T 3.94T 4.66T
Depreciation & Amortization Expense 136.95B 147.39B 153.48B 188.4B 219.15B
Depreciation - - - - -
Amortization of Intangibles - - - - -
Gross Income 683.28B 842.7B 850.32B 785.46B 851B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 531.95B 518.22B 508.9B 491.82B 536.46B
Research & Development 3.6B 3.84B 3.33B - 6.5B
Other SG&A 528.35B 514.38B 505.56B 491.82B 529.96B
Other Operating Expense 9.9B 8.2B 7.7B 42.34B 13.06B
Unusual Expense 75.02B 95.19B 25.56B (5.37B) 24.98B
EBIT after Unusual Expense (75.02B) (95.19B) (25.56B) 5.37B (24.98B)
Non Operating Income/Expense 81.88B 63.3B 124.01B 96.67B 126.83B
Non-Operating Interest Income 35.67B 39.97B 37.17B 40.27B 33.64B
Equity in Affiliates (Pretax) - - - - -
Interest Expense 57.92B 51.65B 56.14B 65.22B 57.7B
Gross Interest Expense 57.92B 51.65B 56.14B 65.22B 57.7B
Interest Capitalized 0 0 0 0 0
Pretax Income 126.04B 272.7B 413.21B 328.39B 379.28B
Income Tax 89.22B 203.9B 172.62B 195.21B 176.65B
Income Tax - Current Domestic 37.57B 249M 11.16B 180.75B 176.46B
Income Tax - Current Foreign 68B 156.65B 175.66B - -
Income Tax - Deferred Domestic (19.26B) 41.19B 218M 14.47B 192M
Income Tax - Deferred Foreign 2.91B 5.81B (14.41B) - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 131.47B 242.14B 232.09B 183.07B 171.24B
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 168.3B 310.94B 472.68B 316.25B 373.86B
Minority Interest Expense 17.92B 4.28B 38.18B 19.63B 23.77B
Net Income 150.38B 306.66B 434.5B 296.62B 350.09B
Extraordinaries & Discontinued Operations (657M) 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (657M) 0 0 0 0
Net Income After Extraordinaries 149.72B 306.66B 434.5B 296.62B 350.09B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 150.38B 306.66B 434.5B 296.62B 350.09B
EPS (Basic) 82.12 168.05 238.10 162.53 192.22
Basic Shares Outstanding 1.82B 1.82B 1.82B 1.83B 1.82B
EPS (Diluted) 82.11 168.05 238.10 162.53 192.21
Diluted Shares Outstanding 1.82B 1.82B 1.82B 1.83B 1.82B
EBITDA 278.38B 463.66B 487.2B 439.71B 520.63B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...
Continue Reading
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...
Continue Reading
Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...
Continue Reading
Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...
Continue Reading
Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...
Continue Reading
Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...
Continue Reading
Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding the Recreational Vehicle Market The recreational vehicle (RV) market has become a beacon for travel enthusiasts, illustrating a profound shift toward enhancing the travel experience. These vehicles offer not just transportation, but a home on wheels, combining adventure with convenience. As of now, the global RV market size is valued significantly, with...
Continue Reading
Ataccama Opens Registration for FWRD 2025 BOSTON — Ataccama, the data trust company, is excited to announce that registration is now open for FWRD 2025, its major virtual event designed for Chief Data Officers (CDOs) and data leaders navigating the complexities of artificial intelligence and data management. This groundbreaking event will take place on November 6 and...
Continue Reading
Exciting Changes in Ticketing with Apple Wallet Live Nation Entertainment’s Ticketmaster has announced a significant enhancement for event ticketing by integrating support for richer tickets within Apple Inc.’s Wallet. This upgrade, stemming from the new features introduced with iOS 18, is set to revolutionize how concert and event goers manage their tickets. What...
Continue Reading
Zealand Pharma's Upcoming Conference Call Zealand Pharma A/S, a prominent biotechnology firm known for its innovative peptide-based medicines, has announced an important event on August 14, 2025. The company will hold a conference call at 2:00 PM CET, equivalent to 8:00 AM ET, to discuss its financial results for the second quarter of 2025. Key Participants in the Call...
Continue Reading
Juniper Biosciences Secures Significant Funding In a remarkable move to propel its innovative projects forward, Juniper Biosciences LLC has successfully closed an oversubscribed and upsized $40 million seed financing round. This effort was spearheaded through its parent company, Juniper Radiopharma LLC, and co-led by NovaCapital alongside several high-net-worth investors...
Continue Reading